RT Journal Article
SR Electronic
T1 Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 1191
OP 1193
DO 10.1136/jcp.2005.031054
VO 59
IS 11
A1 Lear, S
A1 Eren, E
A1 Findlow, J
A1 Borrow, R
A1 Webster, D
A1 Jolles, S
YR 2006
UL http://jcp.bmj.com/content/59/11/1191.abstract
AB The current treatment of primary antibody deficiency (PAD) is the early recognition of the condition and replacement immunoglobulin combined with prompt treatment of infections and complications. The route of administration (intravenous or subcutaneous), dose and frequency of administration of immunoglobulin still vary between centres and countries. Most infections in patients with PAD are reduced but not entirely prevented by replacement immunoglobulin, with sinopulmonary infections accounting for the bulk of the remainder. Although there have been reports of meningitis in patients with PAD before replacement treatment, we describe the first two cases of bacterial meningitis (group B Neisseria meningitidis) on adequate immunoglobulin replacement and discuss the involvement of potential cofactors.